Rinat Neuroscience Corporation
Rinat Neuroscience Corporation was a privately held biotechnology company that discovered and developed antibody-based drugs including:
- Tanezumab (codenamed RN624),[1][2] a monoclonal antibody against nerve growth factor for the treatment of pain
- Ponezumab (codenamed RN1219),[3] a monoclonal antibody against Beta amyloid for the treatment of Alzheimer's disease
- Fremanezumab (codenamed TEV-48125, RN307 and LBR-101),[4][5][6] a monoclonal antibody against Calcitonin gene-related peptide for the treatment of migraines
- Bococizumab (codenamed RN316),[7] a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol
- RN6G, a monoclonal antibody against Beta amyloid for the treatment of Geographic Atrophy in Age-Related Macular Degeneration[8]
- RN909, a monoclonal antibody antagonist of the glucagon receptor for type 2 diabetes (T2DM)[9]
- REGN4018, a novel MUC16xCD3 bispecific T-cell engager for the treatment of ovarian cancer[10]
- PF-04518600 a monoclonal antibody targeting OX40 to enhance T cell functions and inhibit tumor growth[11]
Rinat was founded in 2001 by Arnon Rosenthal,[12][13] who was also Rinat's president, chief scientific office and board director, and Patrick Lynn,[14] following a broad licensing agreement with Genentech,[15] and was acquired by Pfizer in 2006 for approximately $500M.[16][17] Rinat currently operates as an independent biotechnology unit within Pfizer's Worldwide R&D group in South San Francisco.[18]
References
- Vastag, Brian. "Monoclonals expand into neural disorders". Nature.
- Lane, Nancy E.; et al. (2010). "Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee". New England Journal of Medicine. The New England Journal of Medicine. 363 (16): 1521–1531. doi:10.1056/NEJMoa0901510. PMC 6896791. PMID 20942668.
- "Ponezumab". ALZForum.
- "Teva Completes Acquisition of Labrys: Opens Door to a Strong and Novel Migraine Prevention and Treatment Franchise within its CNS Portfolio". Business Wire/Nasdaq.
- Carroll, John. "In biotech trifecta, startup lassos $31M, a CEO and a lead drug from Pfizer". FierceBiotech.
- Leuty, Ron. "Migraine drug developer Labrys targeted by Teva in $825 million deal". San Francisco Business Times.
- Berkrot, Bill; Beasley, Deena. "Experimental Pfizer cholesterol drug promising in study". Reuters.
- "An Investigational Therapy for Geographic Atrophy in Age-Related Macular Degeneration".
- Gumbiner, Barry; Esteves, Brooke; Dell, Vanessa; Joh, Tenshang; Garzone, Pamela D.; Forgie, Alison; Udata, Chandrasekhar (2018). "Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes". Endocrine. 62 (2): 371–380. doi:10.1007/s12020-018-1597-1. PMID 30203123.
- "REGN4018, a novel MUC16xCD3 bispecific T-cell engager for the treatment of ovarian cancer".
- "FIH study of an OX40 agonist mAb PF-04518600 in adult patients with select advanced solid tumors".
- "Arnon Rosenthal Ph.D. - Executive Profile". Bloomberg Businessweek.
- Leuty, Ron. "Alector snags funding in founder's latest attack on Alzheimer's". San Francisco Business Times.
- "Patrick G. Lynn - Executive Profile". Bloomberg Businessweek.
- "Genentech and Rinat Neuroscience Announce Co-Development and Joint Commercialization Agreement for Anti-NGF Antibody for Acute and Chronic Pain". Genentech.
- Pollack, Andrew. "Pfizer to Buy Rinat, a Biotechnology Drug Maker". New York Times.
- "Pfizer to Expand Neuroscience Research with Acquisition of Biotech Company Rinat Neuroscience disorders". Pfizer. Archived from the original on 2015-09-24.
- "Rinat". Pfizer. Archived from the original on 2014-09-01.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.